-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I9OqwuZIrTGkovR/GMcGxkVw+SzVDw3gh714DiqSxs1VcNkPY4sc8kUYiluZlj/B cdegZ/AWfh/SB0BMcoQV8Q== 0001036050-97-000403.txt : 19970627 0001036050-97-000403.hdr.sgml : 19970627 ACCESSION NUMBER: 0001036050-97-000403 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19970613 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 19970626 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-06533 FILM NUMBER: 97630065 BUSINESS ADDRESS: STREET 1: 31 NEWBURY ST STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6178908263 MAIL ADDRESS: STREET 1: 31 NEWBURY STREET STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 8-K 1 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) June 13, 1997 ------------- BOSTON LIFE SCIENCES, INC. -------------------------- (Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826 - ------------------------------------------ ------ ------------------------------------ (State or other jurisdiction of (Commission (I.R.S. Employer Identification No.) incorporation or organization) File No.) 31 Newbury Street, Suite 300 Boston, Massachusetts 02116 - ------------------------------------------ ------------------------------------ (Address of principal executive offices) Zip Code
Registrant's telephone number, including area code (617) 425-0200 --------------- Item 5. Other Events. ------------- On June 13, 1997, Boston Life Sciences, Inc. announced that the U.S. Patent and Trademark Office had issued notices of allowance for several claims within two separate patent applications which had previously been licensed to BLSI by Children's Hospital of Boston, MA. The allowed claims within these patents cover the use of Troponin I to treat angiogenic conditions, and the composition of its licensed Central Nervous System (CNS) growth factor. BLSI is engaged in the research and development of novel treatments for cancer, autoimmune diseases, and central nervous system disorders. Item 7. Exhibits. -------- The following Exhibits are filed as part of this report on Form 8-K: 99.1 Press Release, dated June 13, 1997. SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto authorized. BOSTON LIFE SCIENCES, INC. Dated: June 18, 1997 By:/s/ Joseph Hernon ------------------ Joseph Hernon Chief Financial Officer BOSTON LIFE SCIENCES, INC. CURRENT REPORT ON FORM 8-K EXHIBIT INDEX Exhibit No. Page - ----------- ---- 99.1 Press Release, dated June 13, 1997 5 EX-99.1 2 PRESS RELEASE Exhibit 99.1 FOR IMMEDIATE RELEASE BOSTON LIFE SCIENCES ANNOUNCES NOTICE OF PATENT ALLOWANCES IN ITS CENTRAL NERVOUS SYSTEM REGENERATION AND ANTI-ANGIOGENESIS TECHNOLOGIES BOSTON, MA - JUNE 13, 1997 -- BOSTON LIFE SCIENCES, INC. (NASDAQ: BLSID) announced today that the U.S. Patent and Trademark Office had issued notices of allowance for several claims within two separate patent applications which had previously been licensed to BLSI by Children's Hospital of Boston, MA. The allowed claims within these patents cover the use of Troponin I to treat angiogenic conditions, and the composition of its licensed Central Nervous System (CNS) growth factor. "We are extremely pleased that a Notice of Allowance on the Axogenesis Factor 1 patent has been issued, since we believe that this CNS growth factor is particularly unique in its ability to promote axon growth in the CNS", said Marc E. Lanser, M.D., Chief Scientific Officer of BLSI. "We view the impending issuance of this patent as an important event in support of what we believe is our significant proprietary position in the field of CNS regeneration to use this unique CNS growth factor for the treatment of stroke and spinal cord injuries." "Given our ongoing significant effort on anti-angiogenesis as an exciting approach to the treatment of tumor metastases, we are delighted to have received notice of allowance of the claims related to the use of Troponin to treat angiogenic diseases," stated David Hillson, President and CEO of BLSI. "This notice clearly increases our confidence in continuing to develop this potentially important anti-cancer therapeutic, although any product development process is acknowledged to be lengthy and uncertain," added Mr. Hillson. BLSI is engaged in the research and development of novel therapeutics for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in clinical trials or in pre-clinical development include the above mentioned Altropane; Troponin I, an anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; THERAFECTIN for the treatment of Rheumatoid Arthritis; and transcription factors to control the expression of molecules associated with autoimmune disease and allergies. -----END PRIVACY-ENHANCED MESSAGE-----